Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 2/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 16/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 16/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12590440 | 0.93 | AKR1C3 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1842153 | 0.87 | PSEN1 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1843589 | 0.86 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1842787 | 0.86 | AKR1C3 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12590444 | 0.85 | AKR1C3 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12590457 | 0.85 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1843177 | 0.84 | AKR1C3 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1843300 | 0.83 | AKR1C3 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12590441 | 0.83 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1847460 | 0.83 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968725-B2 | Pyridinyl modulators of γ-secretase | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-06-28 | — | — | US | disclosed |
| US-7968725-B2 | Pyridinyl modulators of γ-secretase | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-06-28 | — | — | US | disclosed |
| US-7968725-B2 | Pyridinyl modulators of γ-secretase | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-06-28 | — | — | US | disclosed |
| EP-2321278-A2 | PYRIDINYL MODULATORS OF y-SECRETASE | Janssen Pharmaceutica, N.V. (BE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010011626-A2 | PYRIDINYL MODULATORS OF ϒ-SECRETASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010011626-A2 | PYRIDINYL MODULATORS OF ϒ-SECRETASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022583-A1 | PYRIDINYL MODULATORS OF gamma-SECRETASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022583-A1 | PYRIDINYL MODULATORS OF gamma-SECRETASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022583-A1 | PYRIDINYL MODULATORS OF gamma-SECRETASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022583-A1 | PYRIDINYL MODULATORS OF gamma-SECRETASE | BACE1, PSEN1, BACE2 | PSEN1 2/4885PSEN2 4/4885APH1B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.